Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 4
1946 17
1947 38
1948 20
1949 26
1950 42
1951 67
1952 126
1953 159
1954 120
1955 115
1956 144
1957 127
1958 114
1959 161
1960 190
1961 219
1962 188
1963 270
1964 557
1965 447
1966 398
1967 587
1968 720
1969 869
1970 803
1971 951
1972 1012
1973 1199
1974 1180
1975 1108
1976 1075
1977 1036
1978 964
1979 1076
1980 1096
1981 1121
1982 1181
1983 1391
1984 1489
1985 1565
1986 1781
1987 1868
1988 2064
1989 2267
1990 2543
1991 2779
1992 2784
1993 3018
1994 2981
1995 3222
1996 3241
1997 3405
1998 3503
1999 3771
2000 3855
2001 3987
2002 3993
2003 4462
2004 4401
2005 4610
2006 4807
2007 4871
2008 5193
2009 5402
2010 5573
2011 5923
2012 6102
2013 6336
2014 6310
2015 6410
2016 6197
2017 5969
2018 5637
2019 5715
2020 6945
2021 6902
2022 6250
2023 5235
2024 1689

Text availability

Article attribute

Article type

Publication date

Search Results

181,473 results

Results by year

Filters applied: . Clear all
Page 1
Evidence-based diagnosis and thrombolytic treatment of cardiac arrest or periarrest due to suspected pulmonary embolism.
Logan JK, Pantle H, Huiras P, Bessman E, Bright L. Logan JK, et al. Am J Emerg Med. 2014 Jul;32(7):789-96. doi: 10.1016/j.ajem.2014.04.032. Epub 2014 Apr 24. Am J Emerg Med. 2014. PMID: 24856738 Review.
A subset of these patients develop cardiac arrest or periarrest due to pulmonary embolism (PE). For these patients, an early, presumptive diagnosis of PE is critical in this patient population because administration of thrombolytic therapy may significantly i …
A subset of these patients develop cardiac arrest or periarrest due to pulmonary embolism (PE). For these patients, an early, presump …
Thrombolytic therapy.
Cade JF. Cade JF. Blood Rev. 1989 Mar;3(1):5-10. doi: 10.1016/0268-960x(89)90020-9. Blood Rev. 1989. PMID: 2495835 Review.
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. ...This protein is the body's own chief plasminogen activator and has been produced by recombinant DNA technology. ...
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. ...This …
Fibrinolytic Enzyme - An Overview.
Abdul Rahim P, Rengaswamy D. Abdul Rahim P, et al. Curr Pharm Biotechnol. 2022;23(11):1336-1345. doi: 10.2174/1389201023666220104143113. Curr Pharm Biotechnol. 2022. PMID: 34983344 Review.
Fibrinolytic agents degrade fibrin through enzymatic and biochemical processes. ...This review deals with the fibrinolytic enzymes, their mechanisms, sources, and their therapeutic potential....
Fibrinolytic agents degrade fibrin through enzymatic and biochemical processes. ...This review deals with the fibrinolytic …
Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.
Kadir RRA, Bayraktutan U. Kadir RRA, et al. Cell Mol Neurobiol. 2020 Apr;40(3):347-355. doi: 10.1007/s10571-019-00737-w. Epub 2019 Sep 24. Cell Mol Neurobiol. 2020. PMID: 31552559 Review.
Stroke continues to be one of the leading causes of mortality and morbidity worldwide. Restoration of cerebral blood flow by recombinant plasminogen activator (rtPA) with or without mechanical thrombectomy is considered the most effective therapy for rescuing …
Stroke continues to be one of the leading causes of mortality and morbidity worldwide. Restoration of cerebral blood flow by recombinant …
Thrombolytic therapy.
Sharma GV, Cella G, Parisi AF, Sasahara AA. Sharma GV, et al. N Engl J Med. 1982 May 27;306(21):1268-76. doi: 10.1056/NEJM198205273062105. N Engl J Med. 1982. PMID: 7040966 Review. No abstract available.
New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.
Maksimenko AV, Tischenko EG. Maksimenko AV, et al. J Thromb Thrombolysis. 1999 Jun;7(3):307-12. doi: 10.1023/a:1008939428688. J Thromb Thrombolysis. 1999. PMID: 10373713 Review.
Increased efficacy of thrombolytic therapy requires a comprehensive search for new and novel therapeutic strategies. ...Long-acting forms of plasminogen activators are being developed and tested in combination with tissue-type plasminogen activator …
Increased efficacy of thrombolytic therapy requires a comprehensive search for new and novel therapeutic strategies. ...Long-a …
Polyphenol-Functionalized Cubosomes as Thrombolytic Drug Carriers.
Yu H, Palazzolo JS, Ju Y, Niego B, Pan S, Hagemeyer CE, Caruso F. Yu H, et al. Adv Healthc Mater. 2022 Nov;11(21):e2201151. doi: 10.1002/adhm.202201151. Epub 2022 Sep 13. Adv Healthc Mater. 2022. PMID: 36037807
The safe administration of thrombolytic agents is a challenge for the treatment of acute thrombosis. ...The lipid cubosomes are loaded with the thrombolytic drug urokinase-type plasminogen activator (uPA) and coated with a low-foul …
The safe administration of thrombolytic agents is a challenge for the treatment of acute thrombosis. ...The lipid cubosomes ar …
Streptokinase and urokinase for the treatment of pleural effusions and empyemas.
Barletta JF. Barletta JF. Ann Pharmacother. 1999 Apr;33(4):495-8. doi: 10.1345/aph.18219. Ann Pharmacother. 1999. PMID: 10332542 Review.
The AWP of streptokinase is $122 for 250,000 units compared with $433 for 250,000 units of urokinase. In the only comparative trial, the average number of instillations was the same, so the cost of therapy with urokinase is significantly higher. ...Further st …
The AWP of streptokinase is $122 for 250,000 units compared with $433 for 250,000 units of urokinase. In the only comparative trial, …
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Prewitt RM, Hoy C, Kong A, Gu SA, Greenberg D, Cook R, Chan SM, Ducas J. Prewitt RM, et al. Am Rev Respir Dis. 1990 Feb;141(2):290-5. doi: 10.1164/ajrccm/141.2.290. Am Rev Respir Dis. 1990. PMID: 2105682
We compared thrombolytic and pulmonary hemodynamic effects of recombinant tissue plasminogen activator (rtPA) and urokinase (UK) in canine micropulmonary thromboembolism. ...We employed two doses of UK, 30,000 U/kg (UK30) and 60,000 U/kg …
We compared thrombolytic and pulmonary hemodynamic effects of recombinant tissue plasminogen activator (rtPA) an …
[Thrombolytic therapy in pulmonary embolism. Indications and therapeutic strategies].
Niedermeyer J, Meissner E, Fabel H. Niedermeyer J, et al. Z Gesamte Inn Med. 1993 Jun-Jul;48(6-7):332-43. Z Gesamte Inn Med. 1993. PMID: 8333230 Review. German.
Thrombolytic therapy is recommended in haemodynamically compromised patients, since it yields accelerated clot lysis and pulmonary reperfusion. ...So far there is no study to prove that thrombolytic therapy significantly reduces mortality in …
Thrombolytic therapy is recommended in haemodynamically compromised patients, since it yields accelerated clot lysis and pu …
181,473 results
You have reached the last available page of results. Please see the User Guide for more information.